Jounce Therapeutics (JNCE) Tops Q4 EPS by 30c, Revenues Beat; Offers FY19 Revenue Outlook Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. GNK
3. NVDA
4. AZN
5. SPCX
6. FNGR
7. PLUR
8. EYPT
9. HIVE
10. GSAT

Go back to Jounce Therapeutics (JNCE) Tops Q4 EPS by 30c, Revenues Beat; Offers FY19 Revenue Outlook Below Consensus

Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

March 6, 2019 6:30 AM EST

- New data from two programs to be presented at AACR -

- New Phase 2 studies to be initiated in 2019 supported by established safety from dose escalation cohorts of vopratelimab (JTX-2011), with ipilimumab and with pembrolizumab -

- Ended 2018 with $195.9 million in cash, cash equivalents and investments -

- Company to host conference call and webcast today at 8:00 AM ET -

CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery... More